Text Size

Phase 2b, Randomized, 3-Month, Dose-Finding Study of Sepetaprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: The ANGEL Study.

Wirta, D.L.; Kuwayama, Y.; Lu, F.; Shao, H.; Odani-Kawabata, N.

  • 2022
  • Journal of Ocular Pharmacology and Therapeutics
View publication
  • Therapeutic Area


  • Categories

    Clinical development

  • Affiliations

    Eye Research Foundation, Newport Beach, California, USA; Fukushima Eye Clinic, Osaka, Japan; Product Development Division (FHL, HS), Santen, Inc., Emeryville, California, USA; Product Development Division (NOK), Santen Pharmaceutical Co., Ltd., Osaka, Japan

Related Publications

Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: 2-year Results from a Randomized, Multicenter Study

Panarelli JF, Moster MR, Garcia-Feijoo J, Flowers BE, Baker ND, Barnebey HS, Grover DS, Khatana AK, Lee B, Nguyen T, Stiles MC, Sadruddin O, Khaw PT.

Omidenepag Isopropyl in Latanoprost Low/Non-Responders with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3, Non-Randomized, Two-Phase, Open-Label Study

Panarelli JF, Bowden EC, Tepedino ME, Odani-Kawabata N, Pei Z, McLaurin EB, Ropo A.

The Development of a SIBS Shunt to Treat Glaucoma

Pinchuk L.

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022